Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment. [electronic resource]
Producer: 20200914Description: 5939-5947 p. digitalISSN:- 2045-7634
- Acrylamides -- therapeutic use
- Adenocarcinoma -- blood
- Aged
- Aniline Compounds -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- blood
- Circulating Tumor DNA -- blood
- ErbB Receptors -- genetics
- Female
- Humans
- Lung Neoplasms -- blood
- Male
- Middle Aged
- Mutation
- Progression-Free Survival
- Protein Kinase Inhibitors -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.